Barrett Lucinda K, Orie Nelson N, Taylor Valerie, Stidwill Raymond P, Clapp Lucie H, Singer Mervyn
Wolfson Institute for Biomedical Research, and the Department of Medicine, University College London, London, UK.
Crit Care Med. 2007 Oct;35(10):2337-43. doi: 10.1097/01.ccm.0000281861.72907.17.
There is escalating interest in the therapeutic use of vasopressin in septic shock. However, little attention has focused on mechanisms underlying its pressor hypersensitivity, which contrasts with the vascular hyporesponsiveness to catecholamines. We investigated whether a long-term rodent model of sepsis would produce changes in endogenous levels and pressor reactivity to exogenous norepinephrine and vasopressin comparable with those seen in septic patients.
In vivo and ex vivo animal study.
University research laboratory.
Male adult Wistar rats.
Fecal peritonitis was induced in conscious, fluid-resuscitated rats. Biochemical and hormonal profiles were measured at time points up to 48 hrs. Pressor responses to intravenous norepinephrine, vasopressin, and F-180, a selective V1 receptor agonist, were measured at 24 hrs. Contractile responses to these drugs were assessed in mesenteric arteries taken from animals at 24 hrs using wire myography. Comparisons were made against sham operation controls.
Septic rats became unwell and hypotensive, with a mortality of 64% at 48 hrs (0% in controls). Plasma norepinephrine levels were elevated in septic animals at 24 hrs (1968 +/- 490 vs. 492 +/- 90 pg/mL in controls, p = .003), whereas vasopressin levels were similar in the two groups (4.5 +/- 0.8 vs. 3.0 +/- 0.5 pg/mL, p = not significant). In vivo, the pressor response to norepinephrine was markedly reduced in the septic animals, but responses to vasopressin and F-180 were relatively preserved. In arteries from septic animals, norepinephrine contractions were decreased (efficacy as measured by maximum contractile response, Emax: 3.0 +/- 0.3 vs. 4.7 +/- 0.2 mN, p < .001). In contrast, the potency of vasopressin (expressed as the negative log of the concentration required to produce 50% of the maximum tension, pD2: 9.1 +/- 0.04 vs. 8.7 +/- 0.05, p < .001) and F-180 (pD2 8.2 +/- 0.04 vs. 7.6 +/- 0.02, p < .001) was enhanced (n > or = 6 for all groups).
This long-term animal model demonstrates changes in circulating vasoactive hormones similar to prolonged human sepsis, and decreased pressor sensitivity to norepinephrine. Ex vivo sensitivity to vasopressin agonists was heightened. This model is therefore appropriate for the further investigation of mechanisms underlying vasopressin hypersensitivity, which may include receptor or calcium-handling alterations within the vasculature.
血管加压素在感染性休克治疗中的应用正受到越来越多的关注。然而,很少有研究关注其升压反应过敏的潜在机制,这与血管对儿茶酚胺的低反应性形成对比。我们研究了长期的啮齿动物脓毒症模型是否会导致内源性水平的变化以及对外源性去甲肾上腺素和血管加压素的升压反应性变化,这些变化与脓毒症患者中观察到的情况相似。
体内和体外动物研究。
大学研究实验室。
成年雄性Wistar大鼠。
在清醒、液体复苏的大鼠中诱发粪便性腹膜炎。在长达48小时的时间点测量生化和激素指标。在24小时时测量对静脉注射去甲肾上腺素、血管加压素和F - 180(一种选择性V1受体激动剂)的升压反应。使用线式肌动描记法在24小时时评估从动物身上获取的肠系膜动脉对这些药物的收缩反应。与假手术对照组进行比较。
脓毒症大鼠出现不适和低血压,48小时时死亡率为64%(对照组为0%)。脓毒症动物在24小时时血浆去甲肾上腺素水平升高(1968±490 vs. 对照组492±90 pg/mL,p = 0.003),而两组血管加压素水平相似(4.5±0.8 vs. 3.0±0.5 pg/mL,p = 无显著差异)。在体内,脓毒症动物对去甲肾上腺素的升压反应明显降低,但对血管加压素和F - 180的反应相对保留。在脓毒症动物的动脉中,去甲肾上腺素收缩作用减弱(以最大收缩反应衡量的效能,Emax:3.0±0.3 vs. 4.7±0.2 mN,p < 0.001)。相比之下,血管加压素(以产生最大张力50%所需浓度的负对数表示,pD2:9.1±0.04 vs. 8.7±0.05,p < 0.001)和F - 180(pD2 8.2±0.04 vs. 7.6±0.02,p < 0.001)的效力增强(所有组n≥6)。
这种长期动物模型显示出循环血管活性激素的变化类似于人类长期脓毒症,并且对去甲肾上腺素的升压敏感性降低。体外对血管加压素激动剂的敏感性增强。因此,该模型适合进一步研究血管加压素过敏的潜在机制,这可能包括血管内受体或钙处理的改变。